01 March 2017 by Gul Ongen

Preliminary ambrisentan tadalafil combination experience

Backround

Upfront ambrisentan(A) tadalafil(T) combination treatment has been shown to be one of the PAH treatment options that reduce the clinical end points in PAH. The aim of this study is to share our preliminary A+T experience.

Method

Seven patients (1M/6F) started A+T treatment, followed up by echocardiography, functional class, pro_BNP, and 6-MWD for a year.

Results

Seven patients (mean age 51±13 years; 6 females) were analyzed. Three diagnosed IPAH, four systemic sclerosis associated PAH. The mean duration of treatment was 15±2.8 months. The pre- and post treatment mean values of particular follow-up parameters were as follows:

 

PASP mmHg

6MWD

meters

proBNP pg/mL

FC I %

FC II %

FC III %

Pre tx

78

349

2888

0

29

71

Followup

63

354

1885

14

57

28

Conclusion

As it is presented above, the combination of A+T in the treatment of PAH shows improvement in certain important parameters. Although statistical analysis could not be performed due to the small number of patients, these findings give the impression of the results of the clinical study are translated to real life experience.

Key Contributors

Ongen H Gul1 , Hacioglu Yonca1, Kılıckıran Avcı Burcak2, Atahan Ersan1, Musellim Benan1, Ongen Zeki2 Istanbul University, Cerrahpasa Medical Faculty, Pulmonary Disease1 and Cardiology2 Departments


Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg